TITLE:
Cyclosporine as a Steroid-Sparing Agent in Thyroid Eye Disease: A Single-Centre Retrospective Review
AUTHORS:
Kit May Chow, Ramzi Ajjan, Khyatisha Seejore, Bernard Chang, Gabriella Guevara
KEYWORDS:
Thyroid Eye Disease, Graves’ Ophthalmopathy, Cyclosporine, Steroid-Sparing, Clinical Activity Score, Immunosuppression, Orbital Inflammation
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.16 No.4,
November
19,
2026
ABSTRACT: Background: Thyroid Eye Disease (TED) is an autoimmune orbital disorder that can cause significant morbidity. Intravenous methylprednisolone (IVMP) is the first-line treatment for active, moderate-to-severe TED, but reactivation following steroid discontinuation remains a challenge. Cyclosporine A (CsA) has been used as a steroid-sparing agent in this setting, yet real-world data on its effectiveness and tolerability remain limited. The aim of this study was to evaluate the steroid-sparing efficacy of CsA in a retrospective cohort of patients with TED. Methods: A retrospective review was performed of all patients treated with CsA for active TED at a single tertiary referral centre. The primary outcome was change in Clinical Activity Score (CAS) from baseline to 3 months, 6 months, and at the time of CsA discontinuation. Secondary outcomes included change in Gorman diplopia score, steroid discontinuation rates, reasons for stopping CsA, and adverse events. Statistical analysis was performed using the Wilcoxon signed-rank test. Results: Twenty-two patients were included (mean age 52.2 years; 72.7% female; 36.4% smokers). All had received prior IVMP (range 1.5 - 7.5 g). The median CAS fell significantly from 3 (IQR 3 - 4) at baseline to 2 (IQR 1 - 3) at 3 months (p = 0.013), 1 (IQR 1 - 2) at 6 months (p = 0.0003), and 1 (IQR 0 - 2) at CsA discontinuation (p = 0.0002). Inactive disease (CAS Conclusions: In this retrospective cohort, CsA was associated with significant reductions in disease activity over time and enabled corticosteroid discontinuation in the majority of patients receiving concomitant steroids. Hypertension was the most frequent adverse event and led to treatment cessation in a meaningful proportion of patients. These findings are consistent with a role for CsA in TED management, particularly in facilitating steroid reduction; prospective controlled studies are needed to confirm its efficacy.